Literature DB >> 24692548

Roles for the mitogen-activated protein kinase (MAPK) phosphatase, DUSP1, in feedback control of inflammatory gene expression and repression by dexamethasone.

Suharsh Shah1, Elizabeth M King, Ambika Chandrasekhar, Robert Newton.   

Abstract

Glucocorticoids act on the glucocorticoid receptor (NR3C1) to repress inflammatory gene expression. This is central to their anti-inflammatory effectiveness and rational improvements in therapeutic index depend on understanding the mechanism. Human pulmonary epithelial A549 cells were used to study the role of the mitogen-activated protein kinase (MAPK) phosphatase, dual-specificity phosphatase 1 (DUSP1), in the dexamethasone repression of 11 inflammatory genes induced, in a MAPK-dependent manner, by interleukin-1β (IL1B). Adenoviral over-expression of DUSP1 inactivated MAPK pathways and reduced expression of all 11 inflammatory genes. IL1B rapidly induced DUSP1 expression and RNA silencing revealed a transient role in feedback inhibition of MAPKs and inflammatory gene expression. With dexamethasone, which induced DUSP1 expression, plus IL1B (co-treatment), DUSP1 expression was further enhanced. At 1 h, this was responsible for the dexamethasone inhibition of IL1B-induced MAPK activation and CXCL1 and CXCL2 mRNA expression, with a similar trend for CSF2. Whereas, CCL20 mRNA was not repressed by dexamethasone at 1 h, repression of CCL2, CXCL3, IL6, and IL8 was unaffected, and PTGS2 repression was partially affected by DUSP1 knockdown. At later times, dexamethasone repression of MAPKs was unaffected by DUSP1 silencing. Likewise, 6 h post-IL1B, dexamethasone repression of all 11 mRNAs was essentially unaffected by DUSP1 knockdown. Qualitatively similar data were obtained for CSF2, CXCL1, IL6, and IL8 release. Thus, despite general roles in feedback inhibition, DUSP1 plays a transient, often partial, role in the dexamethasone-dependent repression of certain inflammatory genes. Therefore this also illustrates key roles for DUSP1-independent effectors in mediating glucocorticoid-dependent repression.

Entities:  

Keywords:  Anti-inflammatory; Corticosteroid; Epithelial Cell; Gene Regulation; Glucocorticoid Receptor; Glucocorticoids; Inflammation; MAP Kinases (MAPKs); MAPK Phosphatase 1 (MKP-1); NR3C1

Mesh:

Substances:

Year:  2014        PMID: 24692548      PMCID: PMC4036371          DOI: 10.1074/jbc.M113.540799

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 2.  Post-transcriptional and nongenomic effects of glucocorticoids.

Authors:  Cristiana Stellato
Journal:  Proc Am Thorac Soc       Date:  2004

3.  Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation.

Authors:  A Ristimäki; K Narko; T Hla
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

4.  The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38.

Authors:  Qun Zhao; Edward G Shepherd; Mary E Manson; Leif D Nelin; Andrey Sorokin; Yusen Liu
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

5.  Anti-inflammatory glucocorticoids: changing concepts.

Authors:  Robert Newton
Journal:  Eur J Pharmacol       Date:  2013-06-07       Impact factor: 4.432

6.  Essential role of MAPK phosphatase-1 in the negative control of innate immune responses.

Authors:  Konstantin V Salojin; Iris B Owusu; Karen A Millerchip; Mark Potter; Ken A Platt; Tamas Oravecz
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

7.  Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA.

Authors:  R Newton; J Seybold; L M Kuitert; M Bergmann; P J Barnes
Journal:  J Biol Chem       Date:  1998-11-27       Impact factor: 5.157

8.  Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses.

Authors:  Hongbo Chi; Sean P Barry; Rachel J Roth; J Julie Wu; Elizabeth A Jones; Anton M Bennett; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

9.  MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock.

Authors:  Qun Zhao; Xianxi Wang; Leif D Nelin; Yongxue Yao; Ranyia Matta; Mary E Manson; Reshma S Baliga; Xiaomei Meng; Charles V Smith; John A Bauer; Cheong-Hee Chang; Yusen Liu
Journal:  J Exp Med       Date:  2005-12-27       Impact factor: 14.307

10.  Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.

Authors:  Michael Hammer; Jörg Mages; Harald Dietrich; Angela Servatius; Norma Howells; Andrew C B Cato; Roland Lang
Journal:  J Exp Med       Date:  2005-12-27       Impact factor: 14.307

View more
  35 in total

1.  Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1β in heart failure.

Authors:  Kenneth Bilchick; Hema Kothari; Aditya Narayan; James Garmey; Abdullah Omar; Brian Capaldo; Coleen McNamara
Journal:  Cardiovasc Res       Date:  2020-06-01       Impact factor: 10.787

2.  Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1.

Authors:  N Dauletbaev; K Herscovitch; M Das; H Chen; J Bernier; E Matouk; J Bérubé; S Rousseau; L C Lands
Journal:  Br J Pharmacol       Date:  2015-10       Impact factor: 8.739

Review 3.  Glucocorticoid receptors: finding the middle ground.

Authors:  Sofie J Desmet; Karolien De Bosscher
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

Review 4.  Glucocorticoid and cytokine crosstalk: Feedback, feedforward, and co-regulatory interactions determine repression or resistance.

Authors:  Robert Newton; Suharsh Shah; Mohammed O Altonsy; Antony N Gerber
Journal:  J Biol Chem       Date:  2017-03-10       Impact factor: 5.157

5.  Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism.

Authors:  Samuel Chao Ming Yeo; Peter S Fenwick; Peter J Barnes; Hai Shu Lin; Louise E Donnelly
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

Review 6.  Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Authors:  Robert Newton; Mark A Giembycz
Journal:  Br J Pharmacol       Date:  2016-11-09       Impact factor: 8.739

7.  Suppression of cytokine production by glucocorticoids is mediated by MKP-1 in human lung epithelial cells.

Authors:  Tiina Keränen; Eeva Moilanen; Riku Korhonen
Journal:  Inflamm Res       Date:  2017-03-15       Impact factor: 4.575

8.  DUSP1 Maintains IRF1 and Leads to Increased Expression of IRF1-dependent Genes: A MECHANISM PROMOTING GLUCOCORTICOID INSENSITIVITY.

Authors:  Suharsh Shah; Elizabeth M King; Mahmoud M Mostafa; Mohammed O Altonsy; Robert Newton
Journal:  J Biol Chem       Date:  2016-08-22       Impact factor: 5.157

Review 9.  Important lessons learned from studies on the pharmacology of glucocorticoids in human airway smooth muscle cells: Too much of a good thing may be a problem.

Authors:  Yassine Amrani; Reynold A Panettieri; Patricia Ramos-Ramirez; Dedmer Schaafsma; Klaudia Kaczmarek; Omar Tliba
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

10.  The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner.

Authors:  T Joshi; M Johnson; R Newton; M A Giembycz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.